Company Profile
Shanghai Bluevascular MedTech Co., Ltd. is a China-based manufacturer of peripheral venous interventional devices, headquartered in Shanghai, China. Founded on January 10, 2018 with Zhu Qing as legal representative, the company operates as a subsidiary of Shanghai MicroPort Endovastec MedTech Co., Ltd. (SSE: 688016), which is itself a subsidiary of MicroPort Scientific Corporation (HKEX: 00853), serving domestic and global peripheral venous markets through a focused product portfolio for deep vein thrombosis (DVT) and iliac vein compression syndrome (IVCS).
Core Products ＆ Technologies
Peripheral Venous Stents ＆ Filters
• Vflower® Venous Stent System: Domestic iliac vein stent featuring integrated braided design and unique rear-release delivery system; NMPA approved (August 2024, No. 国械注准20243131528) via National Innovation Medical Device Special Review Program
• Vewatch® IVC Filter: Inferior vena cava filter for pulmonary embolism prophylaxis; NMPA approved (May 2024)
• Vepack® Filter Retrieval System: Device for IVC filter recovery and removal; NMPA approved (2024)
Balloon ＆ Thrombectomy Systems
• SeaDragon® Peripheral Balloon Dilatation Catheter: China's first approved braided ultra-high-pressure peripheral balloon, rated up to 40atm for iliac-femoral venous and arterial angioplasty; NMPA approved in 2024
• Fishhawk® Mechanical Thrombectomy Device: Single-use thrombectomy catheter with anti-winding隔断 technology for acute iliofemoral DVT; entered NMPA Innovation Special Review Program (2022); NMPA approved (April 27, 2026, No. 国械注准20263010856) as the company's 7th national innovative medical device
• L-REBOA® Aortic Occlusion Balloon Catheter: Resuscitative endovascular balloon occlusion of the aorta device for hemorrhage control; NMPA approved (2025)
Market Position ＆ Certifications
Shanghai Bluevascular MedTech holds an emerging domestic position in China's peripheral venous interventional device market, competing with Boston Scientific, Cook Medical (Zilver Vena), and Cordis in the venous stent segment. Key strengths include:
• 8 years of focused R＆D heritage in peripheral venous intervention since founding
• Innovation pipeline: Multiple products approved via or under NMPA Innovation Special Review Program, including Vflower stent and Fishhawk thrombectomy catheter
• Regulatory compliance: NMPA Class III approvals for venous stents, balloons, filters, and thrombectomy devices; CE certification pathway in progress for select products
• Group synergy: Leverages Endovastec's domestic aortic market leadership and 2,700+ hospital network for commercial distribution
• National procurement: Venous stent selected in National Centralized Procurement at RMB 4,803 per unit (short and long lengths)
Corporate Timeline
2018 — Founded in Shanghai as Endovastec's first subsidiary dedicated to peripheral venous business
2022 — Fishhawk® mechanical thrombectomy device entered NMPA Innovation Special Review Program (green channel)
2024 — Vflower® venous stent (August), Vewatch® IVC filter (May), Vepack® retrieval system, and SeaDragon® balloon received NMPA approval
2025 — Selected in national centralized procurement for peripheral vascular stents; L-REBOA aortic occlusion balloon received NMPA approval
2026 — Fishhawk® thrombectomy device approved by NMPA (April 27) as 7th national innovative medical device; Endovastec optimized equity structure by transferring employee-holding platform shares to strategic partners (March), maintaining 65% control
Target Markets ＆ Applications
• Iliac Vein Compression Syndrome (IVCS): Vflower stenting for May-Thurner syndrome and chronic venous obstruction
• Deep Vein Thrombosis (DVT): Fishhawk thrombectomy for acute iliofemoral DVT; Vflower stenting for post-thrombotic syndrome
• Pulmonary Embolism Prophylaxis: Vewatch IVC filter placement in high-risk DVT patients
• Venous Angioplasty: SeaDragon balloon dilatation for iliac-femoral venous and arterial stenosis, including stent post-dilatation
• Trauma Hemorrhage Control: L-REBOA aortic occlusion balloon for resuscitative endovascular control of non-compressible torso hemorrhage
Contact Information
Global Headquarters
Address: Room 102, Building 1, No. 3399 Kangxin Highway, Pudong New Area, Shanghai 201318, China
Telephone: +86 21 3813 9300
Email: xueli.hu@endovastec.com
Parent Company
Shanghai MicroPort Endovastec MedTech Co., Ltd.
Address: No. 3399 Kangxin Highway, Pudong New Area, Shanghai 201318, China
Stock: SSE: 688016
Website: endovastec.com
Investor Relations: irm@endovastec.com
